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Background: 30-day mortality (30DM) has been suggested as a clinical indicator of the avoidance of harm
in palliative radiotherapy within the NHS, but no large-scale population-based studies exist. This large
retrospective cohort study aims to investigate the factors that inﬂuence 30DM following palliative radio-
therapy and consider its value as a clinical indicator.
Methods: All radiotherapy episodes delivered in a large UK cancer centre between January 2004 and
April 2011 were analysed. Patterns of palliative radiotherapy, 30DM and the variables affecting 30DM
were assessed. The impact of these variables was assessed using logistic regression.
Results: 14,972 palliative episodes were analysed. 6334 (42.3%) treatments were delivered to bone
metastases, 2356 (15 7%) to the chest for lung cancer and 915 (5.7%) to the brain. Median treatment time
was 1 day (IQR 1–7). Overall 30DM was 12.3%. Factors having a signiﬁcant impact upon 30DM were sex,
primary diagnosis, treatment site and fractionation schedule (p < 0.01).
Conclusion: This is the ﬁrst large-scale description of 30-day mortality for unselected adult palliative
radiotherapy treatments. The observed differences in early mortality by fractionation support the use
of this measure in assessing clinical decision making in palliative radiotherapy and require further study
in other centres and health care systems.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 115 (2015) 264–271.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Half of all radiotherapy treatment episodes in England in 2012
were delivered with palliative intent (65,580 episodes) [1].
Palliative radiotherapy is widely used to relieve symptoms from
either the primary tumour or sites of metastatic disease in
advanced cancer. Clinical trials have demonstrated that hypofrac-
tionated treatment provides equivalent symptomatic beneﬁt to
longer courses, with limited toxicity [2]. The decision to fractionate
treatment, with increased acute toxicity and treatment burden, is
sometimes made when it is considered necessary to relieve symp-
toms or with the aim of durable disease control, although the evi-
dence base for this approach is limited. The balance between
symptomatic beneﬁt and the opportunity costs associated with
excessive interventions must, therefore, be carefully considered
and studied.
Many factors may inﬂuence the decision to offer and to frac-
tionate palliative radiotherapy. These include the performancestatus of the patient, anatomical site of disease, primary diagnosis,
co-morbidity, age, access to a clinical oncology opinion, travelling
time to the treatment centre, clinician speciﬁc factors (including
ﬁnancial incentives) and the estimated life expectancy of the
patient [3]. However many of these factors are not prospectively
recorded in national datasets.
Studies have shown that oncologists are poor at predicting sur-
vival of patients with advanced cancer with a tendency to be overly
optimistic [4,5]. This may expose terminally ill patients to the bur-
den of longer fractionated courses of radiotherapy [5,6]. Such
overly aggressive cancer care at the end of life has a detrimental
effect on quality of life and has previously been suggested as a
quality of care issue [7,8]. Conversely, fear of over treatment
amongst medical colleagues has also been cited as a possible factor
reducing access to palliative radiotherapy [9].
The palliative intent of treatment in patients with symptoms of
advanced cancer means it is inevitable that early mortality due to
disease progression will occur in some patients. The NHS policy
document, ‘Improving outcomes: A strategy for cancer’, proposed
mortality within 30-days of treatment (a commonly used metric
in other health interventions) as a clinical indicator to assess the
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studies examining 30-day mortality (30DM) in palliative radio-
therapy showed signiﬁcant mortality in some groups [11,12], but
no large population-based studies have been reported. These stud-
ies do not consider the relationship between fractionation and out-
comes, focussing on access to treatment. Prognostic models for life
expectancy amongst the general cancer population [13,14] and
speciﬁcally death within 30 days of palliative radiotherapy [15]
have recently been published. However these are not used in rou-
tine clinical practise.
Alongside the need to ensure avoidable harm is minimised,
there is a need for global healthcare systems to justify treatments
in terms of value for money. Excessive fractionation may be con-
sidered in both these contexts (hypofractionation being increas-
ingly advocated in the USA) [16]. Measures which can aid the
assessment of the appropriateness of treatment are, therefore,
needed.
The use of 30DM as a clinical indicator for the avoidance of
harm, through appropriate patient selection, in palliative radio-
therapy has not previously been demonstrated. This study investi-
gated the rate of 30DM following palliative radiotherapy in a single
cancer centre serving a population of 2.8 million over a 7 year per-
iod and considered its value as a clinical indicator.Methods
All radiotherapy episodes delivered in a large UK cancer centre
(Leeds Cancer Centre), between January 2004 and April 2011, were
identiﬁed using the electronic patient record system (Patient
Pathway Manager (PPM)). PPM collates and prospectively inte-
grates electronic information on all cancer patients treated within
the centre; patient (date of birth and sex) and treatment informa-
tion (date of treatment, planned fractionation, dose, intent of treat-
ment and site of treatment) were extracted for this analysis.
These data were then linked to the cancer registrations held by
the National Cancer Registration Service (Northern and Yorkshire)
and diagnostic, death and socioeconomic status (SES) information
was extracted for all linked records. SES was categorised on the
basis of rank quintile of deprivation score (Index of Multiple
Deprivation (IMD), ONS 2010 version) [17], for the Lower Super
Output Area (population deﬁned geographical region of approxi-
mately 1500 people [18]) the patient lived in at diagnosis.
Leeds Cancer Centre (LCC) is a university afﬁliated centre serv-
ing a population of 2.8 million. The number of clinical oncologists
increased from 18 to 30 during the study period. All oncologists
are site specialised to a maximum of three primary diagnostic
groups and are trained in the use of palliative radiotherapy. LCC
is resourced through a national NHS tariff system where the
reimbursement of the centre reﬂects the complexity of treatment
planning and separately the number of fractions with complexity
of treatment delivery. LCC were early adopters of the evidence sup-
porting hypofractionation within palliative radiotherapy.
Throughout the study period treatment has been delivered within
well-deﬁned clinical protocols e.g., palliative radiotherapy for
uncomplicated bone metastases is delivered as a single fraction
unless there is clear justiﬁcation for a fractionated high dose
approach. Departmental clinical protocols and a robust electronic
patient record allow the study cohort to be deﬁned.Deﬁnition of palliative intent
Treatment intent was identiﬁed as palliative by the treating
clinician (centre policy) or if delivered in less than ﬁve fractions
(exceptions to this were identiﬁed e.g., stereotactic body radiother-
apy). The site treated was allocated as bone, brain, chest, soft tissue(e.g., treatment to the chest for oesophageal cancer), or unknown
on the basis of the treatment site protocol (a free text ﬁeld entered
at the time of treatment), the diagnosis and intention of treatment.
In order to limit this investigation to adult palliative radiother-
apy treatments, for solid organ tumours and to ensure data quality,
a number of exclusions were made (Fig. 1). Radical treatments
(24,516), episodes with incomplete data (540), treatments for
benign diagnoses (37), non-melanomatous skin cancer (196) and
haematological diagnoses (901) were excluded. Within the centre
patients under the age of 25 are treated within the paediatric
and young adolescent practice, 96 episodes delivered to this group
were also excluded. Where multiple palliative treatments were
delivered with the same start date, these were amalgamated into
a single record (having been related to a single clinical decision).
The fractionation allocated to this event was the largest of the con-
current treatments, this being the more signiﬁcant clinical deci-
sion. 1534 episodes were amalgamated with another record in
this way and considered as a single episode. Where overlapping
treatment episodes were delivered with differing start dates it is
not possible to know if these relate to a single clinical decision.
For clarity these were considered separately.
The primary diagnosis was categorised into seven groups based
on the most commonly occurring tumours. The major primary
diagnoses were lung, breast, prostate, colorectal, bladder and
oesophagus, with a separate category, ‘other’, consisting of all
other cancer diagnoses and those patients with multiple, non-coin-
cident diagnoses.30-day mortality and survival
The proportion dying within 30-days from treatment start was
assessed for all treatments within the cohort and by numbered
courses in relation to fractionation delivered, primary diagnosis
and site treated. The Chi-squared test was used to assess the
impact of various factors upon early mortality. A logistic regression
model was used to investigate the factors associated with death
within 30-days of the start of palliative radiotherapy. The depen-
dent variable, death within 30-days, was considered as a binary
outcome. Covariates (explanatory variables) in the model included,
age at start of radiotherapy, sex, socioeconomic status, site of the
primary tumour, site of irradiation, fractionation pattern and year
of treatment.
Survival was calculated from the start of each palliative radio-
therapy episode to date of death or when censored (30th April
2012). The start date of treatment was used as it is closer to the
clinical decision to treat than the end of treatment and provides
a uniform time point across all fractionation regimens, aligning
with NCEPOD systemic therapy methodology [19]. As individuals
who underwent multiple sequential treatment episodes had, by
deﬁnition, to survive all previous treatments and to ensure people
could not enter survival analyses twice the univariate logistic
regression model and illustrative Kaplan–Meier survival curves
were produced based on ﬁrst and second treatment episodes sepa-
rately. Multivariate analysis considered only the ﬁrst treatment
episode. Univariate logistic regression was also carried out for all
treatment episodes combined, this overall analysis is likely to be
a closer reﬂection of the measure as applied in future, on a pop-
ulation level; including every clinical decision within the cohort.
Statistical analyses were carried out using STATA IC 13.Results
42,792 radiotherapy treatment episodes were identiﬁed. Within
this a total of 18,275 palliative treatment episodes, delivered to
12,240 individuals, were identiﬁed. Of these, 3303 (18.1%) episodes
Total 42,792 episodes
Non-palliave episodes 24,516
18,276 palliave episodes 
(12,240 paents)
Incomplete data 218 episodes 
(138 paents)
No registry link 322 episodes 
(227 paents)
17,736 episodes 
(11,875 paents) Benign diagnoses
37 episodes (30 paents)
Non-melanoma skin cancer 
196 episodes (147 paents)
Haematological diagnoses
901 episodes (550 paents)
<25 years old 
96 episodes (52 paents)
16,506 episodes
(11,096 paents)
1,534 episodes amalgamated 
with another episode - mulple 
treatments received with the 
same start date
14,972 episodes
(11,096 paents)
Fig. 1. Consort diagram demonstrating exclusions from the study population.
266 30 day mortality in palliative radiotherapyin 1144 individuals were excluded (Fig. 1), leaving a study pop-
ulation of 14,972 episodes delivered to 11,096 people.
Table 1 shows the characteristics of the population undergoing
palliative radiotherapy. The median age at treatment was 70 years
(range 25–101). The majority of palliative radiotherapy episodes
(55.3%) were delivered to men. Lung (25.3%), breast (14.7%), pros-
tate (14.5%) and colorectal (5.2%) cancers were the most frequently
treated primary diagnoses. The commonest irradiated site was
bone with 4407 individuals receiving 6334 (42.3%) courses of
treatment to bone alone or bone combined with another site.
Soft tissue (3691 (24.7%)) and chest (3628 (24.2%)) were the next
most commonly irradiated sites.
61.9% of patients received treatment consisting of four or less
radiotherapy fractions (50.5% single and 11.4% 2–4 fractions).
23.7% of patients received ﬁve fractions, 2.2% received 6–9 treat-
ments and 12.3% 10 or more fractions.30-day mortality and survival
Overall, 1846 (12.3%) individuals died within 30 days of the
initiation of a course of palliative radiotherapy. Variations of
30DM in relation to the characteristics of the population and treat-
ment episodes are shown in Table 2. The median survival time
for the whole cohort was 169 days (Inter-Quartile Range (IQR)
67–436 days). Signiﬁcant variation in survival patterns was seen
however in relation to both the primary diagnosis and fractiona-
tion pattern (Fig. 2 and Supplementary Fig. 1S respectively).
Table 3, Fig. 3 and Supplementary Fig. 2S show patterns of
radiotherapy fractionation, 30DM and survival following treatment
to bone. Overall 30DMwas 14.1%; there was signiﬁcant variation in
relation to primary diagnosis and fractionation pattern (p < 0.001).
Palliative radiotherapy to the chest for lung cancer accounted
for 2356 (15.7%) treatments and was associated with 30DM of
14.0%, this was signiﬁcantly related to fractionation, p < 0.01.
Median treatment time for all palliative treatments for lung cancer
to the chest was 8 days (IQR 1–12). The most commonly used frac-
tionation schemes reﬂect local protocols: 1 (32%), 2 (30%), 5
(13.72%), 12 (8.64%) and 13 (7.70%).
915 (5.65%) episodes of palliative radiotherapy to the brain
were delivered within the cohort, of these 68 were accompaniedby treatment to a second site. The two most frequently treated
metastatic diagnoses were breast and lung cancer (205 (22.4%)
and 192 (21.0%) respectively of total) with primary brain tumours
accounting for 160 (17.5%) treatments. Overall 30DM was 11.2%,
with breast, lung, and primary brain cancers having 30DM of
11.2%, 15.1%, and 5.6% respectively (Supplementary Material,
Fig. 3S).
Signiﬁcant variation in 30DM was apparent in relation to sex,
age, primary diagnosis, treatment site, IMD and fractionation
schedule adopted. Age and IMD did not retain their signiﬁcance
in multivariate analysis (Supplementary Material Table 3S).
Socioeconomic status (SES) (as measured by IMD) has been shown
to impact signiﬁcantly upon cancer outcomes [20], the reasons for
this are not entirely clear however SES may be a surrogate for co-
morbidity. Females had a 16% reduction in the odds of death within
30 days compared to males (Odds Ratio (OR) 0.84, 95% Conﬁdence
Interval (CI) 0.74–0.96, p = 0.010) even after adjustment for other
case mix factors. A statistically signiﬁcant relationship between
increasing fractionation schedules and reduction in the odds of
death within 30-days was observed. Those receiving 10 or more
fractions were 90% less likely to die within 30-days of the start
of radiotherapy compared to those receiving just one fraction
(OR 0.10, 95% CI 0.08–0.14, p < 0.001). Of note there was no signiﬁ-
cant variation in early mortality with time (p = 0.391).Discussion
This is the ﬁrst large, population-based study investigating
30DM following palliative radiotherapy in a single centre that is
the sole provider of radiotherapy to a large population. An overall
30 DM rate of 12.3% was observed, aligning well with other
recently published data for ﬁrst palliative radiotherapy treatments
[13].
In this cohort of patients the site most frequently irradiated was
bone. Overall 30DM for these treatments was 14.1%. The literature
suggests the median time to treatment beneﬁt following palliative
radiotherapy to bone is 14 days, with response rates of between
50% and 70% [21,22]. The risk of pathological fracture and the need
for re-treatment, following single fraction radiotherapy to bone
metastases may contribute to the use of fractionated radiotherapy
Table 1
Characteristics of the study population. The majority of the population underwent a single episode of palliative radiotherapy, but 2625 individuals underwent two or more
episodes (3876 episodes). Only 772 patients received three or more courses. Due to the limited size of this latter population information is presented by ﬁrst episode, second
episode and overall within the cohort.
Characteristic Episode number All episodes
1 2
n % n % n %
Age at initial palliative radiotherapy 650 847 7.6 275 10.5 1273 8.5
51–60 1766 15.9 490 18.7 2529 17.0
61–70 3051 27.5 769 29.3 4197 28.2
71–80 3439 31.0 736 28.0 4503 30.2
>80 1993 18.0 355 13.5 2470 16.6
Sex Male 6053 54.6 1478 56.3 8244 55.3
Female 5042 45.4 1147 43.7 6727 45.1
IMD category Most deprived 2663 24.0 574 21.9 3501 23.5
2 2194 19.8 515 19.6 2955 19.8
3 1849 16.7 425 16.2 2466 16.6
4 2318 20.9 565 21.5 3157 21.2
Most afﬂuent 1841 16.6 504 19.2 2606 17.5
Unknown 231 2.1 42 1.6 287 1.9
Primary cancer diagnosis Other 3997 36.0 852 32.5 5185 34.8
Lung 3070 27.7 548 20.9 3770 25.3
Breast 1378 12.4 478 18.2 2186 14.7
Prostate 1232 11.1 533 20.3 2154 14.5
Colorectal 631 5.7 120 4.6 778 5.2
Oesophagus 414 3.7 51 1.9 468 3.1
Bladder 374 3.4 44 1.7 431 2.9
Site of irradiation Multiple 892 8.0 285 10.9 1339 9.0
Bone 3321 29.9 1294 49.3 5379 36.1
Brain 704 6.3 106 4.0 846 5.7
Chest 3224 29.1 337 12.8 3628 24.3
Soft tissue 2901 26.1 576 21.9 3691 24.8
Unknown 54 0.5 27 1.0 89 0.6
Fractionation 1 4813 43.4 1759 67.0 7558 50.5
2–4 1503 13.5 157 6.0 1706 11.4
5 1763 15.9 585 22.3 3547 23.7
6–9 299 2.7 24 0.9 325 2.2
P10 1718 15.5 100 3.8 1836 12.3
Year of treatment 2004 1636 14.7 272 10.4 1982 13.2
2005 1489 13.4 386 14.7 2071 13.8
2006 1430 12.9 362 13.8 1990 13.3
2007 1345 12.1 340 13.0 1847 12.3
2008 1535 13.8 330 12.6 2024 13.5
2009 1498 13.5 399 15.2 2086 13.9
2010 1666 15.0 398 15.2 2274 15.2
2011 497 4.5 138 5.3 698 4.7
Total 11,096 74.1 2625 17.5 14,972 100.0
K. Spencer et al. / Radiotherapy and Oncology 115 (2015) 264–271 267in this setting. Median time to re-treatment has been reported to
be 25 weeks after a single fraction [23]. International evidence
strongly favours the use of single fraction treatments in uncompli-
cated bone metastases [21,24]. Our early mortality outcomes sug-
gest this evidence base has been appropriately applied in this study
population. Fractionated courses of radiotherapy to bone were
associated with signiﬁcantly lower 30DM.
Palliative radiotherapy to the brain had a 30DM of 11.6% overall.
Despite the selective use (640 episodes, 610 deaths) of palliative
radiotherapy to the brain for some poor prognosis groups within
our cohort, early mortality remains high (e.g., melanoma (21.9%),
unknown primary (24.0%) (data not shown)). The beneﬁt of whole
brain radiotherapy for metastases, as compared to supportive care
alone, has not been assessed in randomised controlled trials in the
CT era [25], the ﬁnal outcome of the QUARTZ trial is awaited [26].
30DM for lung cancer patients treated with palliative radiother-
apy was 17.3% (similar to equivalent ﬁgures published in the USA
[12]). Those receiving treatment to the primary had a 30DM of
14.1%, which was signiﬁcantly related to fractionation (p < 0.01).
30DM following 1–2 fraction treatments (22.5%) was markedly
higher than that following ten or more fraction treatments(2.5%). Median time to symptom improvement following thoracic
radiotherapy for NSCLC is approximately 1–2 months [27,28].
Excessive fractionation in poor performance status, lung cancer
patients cannot be justiﬁed given well documented evidence sup-
porting the use of hypofractionation for equivalent symptom con-
trol in this group [28].
30DM varies signiﬁcantly with primary diagnosis, the site being
irradiated, patient sex and the fractionation pattern chosen.
Greater use of more fractionated treatments, increased treatment
burden and potentially higher acute toxicity are harder to justify
in diagnoses with poor prognosis. There are a limited number of
palliative settings in which more fractionated treatments are
known to improve survival. We believe that the variation demon-
strated with fractionation reﬂects appropriate clinical decision
making, encompassing predicted prognosis, in the context of clini-
cal protocols which in themselves reﬂect the underpinning evi-
dence. This supports the use of 30DM as a measure of clinical
decision making in palliative radiotherapy.
Survival with symptomatic disease has increased with increas-
ing systemic therapy options. It is unclear however if the point
within the disease trajectory at which palliative radiotherapy is
Table 2
30-day mortality in relation to the characteristics of the population (as in Table 1, episodes are considered as ﬁrst, second and overall within the cohort).
Characteristic Episode 1 Episode 2 All episodes
n Deaths
within
30 days
P value n Deaths
within
30 days
P value n Deaths
within
30 days
P value
n % n % n %
Age at initial palliative radiotherapy 650 847 85 10.04 0.110 275 40 14.55 0.084 1273 141 11.08 0.010
51–60 1766 212 12.00 490 70 14.29 2529 327 12.93
61–70 3051 382 12.52 769 116 15.08 4197 547 13.03
71–80 3439 438 12.74 736 92 12.50 4503 573 12.72
>80 1993 219 10.99 355 33 9.30 2470 258 10.45
Sex Male 6053 795 13.13 <0.001 1478 215 14.55 0.045 8244 1110 13.46 <0.001
Female 5042 541 10.73 1147 136 11.86 6727 736 10.94
IMD category Most deprived 2663 332 12.47 0.148 574 87 15.16 0.079 3501 459 13.11 0.025
4 2194 283 12.90 515 82 15.92 2955 390 13.20
3 1849 233 12.60 425 53 12.47 2466 313 12.69
2 2318 267 11.52 565 65 11.50 3157 367 11.62
Most afﬂuent 1841 191 10.37 504 56 11.11 2606 278 10.67
Unknown 231 30 12.99 42 8 19.05 287 39 13.59
Site of primary Multiple and Other 3997 479 11.98 <0.001 852 108 12.68 <0.001 4542 643 14.16 <0.001
Lung 3070 489 15.93 548 133 24.27 3770 652 17.29
Breast 1378 92 6.68 478 32 6.69 2186 152 6.95
Prostate 1232 89 7.22 533 41 7.69 2154 161 7.47
Colorectal 631 72 11.41 120 22 18.33 778 99 12.72
Oesophagus 414 50 12.08 50 6 12.00 468 59 12.61
Bladder 374 65 17.38 44 9 20.45 431 80 18.56
Site of irradiation Multiple 892 173 19.39 <0.001 285 46 16.14 <0.001 1339 242 18.07 <0.001
Bone 3321 460 13.85 1294 163 12.60 5379 715 13.29
Brain 704 71 10.09 106 19 17.92 846 95 11.23
Chest 3224 381 11.82 337 73 21.66 3628 467 12.87
Soft tissue 2901 241 8.31 576 46 7.99 3691 313 8.48
Unknown 54 10 18.52 27 4 14.81 89 14 15.73
Fraction group 1 4813 873 18.14 <0.001 1759 259 14.72 <0.001 7558 1265 16.74 <0.001
2–4 1503 166 11.04 157 31 19.75 1706 203 11.90
5 1763 235 13.33 585 54 9.23 3547 309 8.71
6–9 299 16 5.35 24 2 8.33 325 18 5.54
P10 1718 46 2.68 100 5 5.00 1836 51 2.78
Year of treatment 2004 1636 187 11.43 0.745 272 35 12.87 0.865 1982 232 11.71 0.719
2005 1489 197 13.23 386 51 13.21 2071 278 13.42
2006 1430 178 12.45 362 56 15.47 1990 258 12.96
2007 1345 161 11.97 340 40 11.76 1847 224 12.13
2008 1535 181 11.79 330 42 12.73 2024 240 11.86
2009 1498 186 12.42 399 50 12.53 2086 257 12.32
2010 1666 186 11.16 398 59 14.82 2274 273 12.01
2011 497 60 12.07 138 16 11.59 698 84 12.03
Total 11,096 1336 12.04 2625 351 13.37 14,972 1846 12.33
268 30 day mortality in palliative radiotherapydelivered has changed. Lack of variation in early mortality with
time demonstrated here suggests that clinical decision making
near the end of life is stable.
We have shown that it is possible to audit 30DM, in a large
unselected population. The size of this dataset allows analysis of
subgroups by diagnosis and site treated whilst also maintaining
statistical power. In addition, the single centre from which the data
were derived was an early adopter of the evidence supporting the
hypofractionation of palliative radiotherapy (increasingly advo-
cated globally, including in the USA) [16] and patients were treated
within site speciﬁc teams, to consistent clinical protocols (adopted
at the start of the study period). This study has some limitations:
 It reﬂects practice within a single, large NHS centre.
 Planned fractionation was used for all analyses as it most clo-
sely reﬂects the clinical decision to treat, however it may not
always be the fractionation actually delivered. Delivered frac-
tionation was not available across the whole cohort. If, in the
future, such data can be captured the strength of any analyses
undertaken would be increased. Data within the electronic patient record reﬂect routine clinical
practice and were not prospectively coded for research pur-
poses. The allocation of target tissue and intent of treatment
was based upon ﬁxed algorithms. Manual review, by investigat-
ing clinicians, of a sample of cases, revealed high levels of con-
cordance of these ﬁelds (results not shown) indicating
allocation algorithms were robust. A database with deﬁned cod-
ing rules, to include not only anatomical site but also target tis-
sue and re-irradiation would also be beneﬁcial. Whilst the
current national Radiotherapy Dataset (RTDS) includes coding
of anatomical site these data are inadequate due to variations
in the application of the coding rules.
It has previously been shown that chemotherapy prescribing
behaviour among medical oncologists can be inﬂuenced by feeding
back early mortality outcomes [5,7,29,30]. Oncologists prescribing
palliative radiotherapy often do not have an opportunity to follow
up individual patients, so providing feedback in the form of 30DM
outcomes for palliative radiotherapy to clinicians or teams may be
beneﬁcial. A future analysis of 30DM within the RTDS would also
Fig. 2. Survival and 30 DM following the start of palliative radiotherapy in relation to primary diagnosis.
Table 3
30-day mortality following palliative radiotherapy to bone.
Characteristic Episode 1 Episode 2 All episodes
n Deaths within
30 days
n Deaths within
30 days
n Deaths within
30 days
n % n % n %
Fraction group 1 3292 558 17.0 1005 123 12.2 4863 744 15.3
2–4 103 15 14.6 26 1 3.8 145 19 13.1
5 825 95 11.5 198 22 11.1 1117 125 11.2
6–9 6 0 0.0 2 0 0.0 9 0 0.0
P10 181 3 1.7 12 0 0.0 200 6 3.0
Primary diagnosis Breast 821 62 7.6 284 13 4.6 1293 90 7.0
Colorectal 238 36 15.1 40 8 20.0 285 46 16.1
Lung 784 197 25.1 153 33 21.6 979 237 24.2
Prostate 966 64 6.6 419 39 9.3 1664 121 7.3
Renal 196 25 12.8 51 7 13.7 287 40 13.9
Site of irradiation Bone 3734 532 14.2 1066 123 11.5 5379 715 13.3
Multiple bony sites 538 113 21.0 143 18 12.6 779 144 18.5
Bone and another site 135 29 21.5 34 5 14.7 176 35 19.9
Total 4407 674 15.3 1243 146 11.7 6334 894 14.1
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policy setting and commissioning. Outlying results would merit
further study to determine the underlying causes and whether this
reﬂected appropriate variation in practise, reﬁnement of this
assessment process is anticipated over time.
NCEPOD [19] in surgery and chemotherapy has led to the rou-
tine practise of a retrospective review of all deaths within 30 days.
We would recommend an analogous approach, however for single
fraction palliative radiotherapy this may be impractical due to the
high numbers (16.7%). In those receiving a single fraction the bur-
den of treatment is minimal but the potential for beneﬁt within
30 days still signiﬁcant. An earlier time point, possibly mortality
within 14 days (suggested from the survival curves in Fig. 2S
(Supplementary Material)), may be more pragmatic for a
retrospective case note review. The variation in treatment burden
and incremental beneﬁts with fractionation must be borne in mind
when considering 30DM outcomes. Whilst many factors may con-
tribute to this decision making process clinicians must be vigilant
to the risk of early mortality when deciding to fractionate palliative
treatments. Practise will vary, with evidence demonstrating the
impact of ﬁnancial incentives upon the fractionation ofradiotherapy [3]. These may be in direct conﬂict with the need to
reduce treatment burden for terminally ill patients. As the avail-
ability of highly conformal radiotherapy increases, the use of high
dose, hypofractionated palliative radiotherapy will increase. The
beneﬁts in terms of reduced treatment burden (both from reduced
normal tissue toxicity and decreased visits) are clear, however the
cost implications for the department are signiﬁcant and careful
case selection will remain important.
30DM has been recommended as a clinical indicator of the
avoidance of harm in palliative radiotherapy. It is suited to this
in a number of ways: It is objective, clinically relevant, measurable
in a timely manner at a population level and may encourage
improvements both in the avoidance of harm and cost-effective-
ness of palliative radiotherapy services. However, there are lim-
itations to the use of 30DM. It is a single outcome measure;
patient reported outcomes of symptomatic beneﬁt and re-irradia-
tion rates would be valuable as complimentary measures to pro-
vide reassurance that patients were not being undertreated.
More fractionated palliative radiotherapy would be expected to
have a lower 30DM but by contrast any move to reduce 30DM
without reference to fractionation patterns may have a detrimental
Fig. 3. Survival and 30 DM following palliative radiotherapy to bone by fractionation pattern (6–9 fraction treatments are not included here due to small numbers (n = 6)).
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therapy. There will be considerable debate about what constitutes
optimal 30DM. Future work, involving more in depth analysis of a
smaller population, allowing assessment of performance status,
patient preferences and outcomes would be valuable. This, along-
side an assessment of the impact of implementing 30DM, would
allow validation of the measure as a clinical indicator.
This is the ﬁrst large-scale description of 30-day mortality for
unselected adult palliative radiotherapy treatments. Signiﬁcant
variation is demonstrated with diagnosis, sex, treatment site and,
importantly, fractionation. In this setting, a measure which can
help to assess the appropriateness of treatment and avoidance of
harm (as demanded by providers of health care) [10] is required.
30DM has a signiﬁcant value as a retrospective measure of depart-
mental palliative radiotherapy outcomes when considered along-
side fractionation patterns. Clearly separated 30DM outcomes by
fractionation would provide reassurance that clinical decision
making was appropriate. It does not attempt to assess or guide
individual clinical decisions. The observed differences in early mor-
tality by fractionation support further study in other centres and
health care systems. Our results suggest it is of value in assessing
department wide clinical decision making in palliative radiother-
apy providing parity with the early metrics used in other health-
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